NCT00093483View on ClinicalTrials.gov

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Leukemia
Interventions
BIOLOGICAL

filgrastim

Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.

DRUG

arsenic trioxide

IV over 1 hour on day 1

DRUG

cytarabine

IV over 1 hour every 12 hours on days 1-6

DRUG

idarubicin

IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT00093483 - Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter